Alpine Immune Sciences Announces Participation in September Investor Conferences

Rhea-AI Summary

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) will present at several investor conferences in September 2021. Key events include the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, Oppenheimer Fall Healthcare Summit on September 20, and Cantor Global Healthcare Conference on September 29. Each presentation will be available via webcast on the company's investor relations website. Alpine is focused on innovative immunotherapy treatments for cancer and autoimmune diseases, emphasizing collaborations and a diverse pipeline.

Positive

• Participation in multiple investor conferences boosts visibility.
• Availability of webcasts enhances transparency for investors.
• Commitment to innovative therapies reflects strong market positioning.

Negative

• None.

SEATTLE--(BUSINESS WIRE)-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that members of its management team will present at the following investor conferences in September 2021:

H.C. Wainwright 23^rd Annual Global Investment Conference
Date: Monday, September 13, 2021
Time: Available on demand beginning 7:00 a.m. ET/4:00 a.m. PT
Event: Company Presentation

Oppenheimer Fall Healthcare Summit
Date: Monday, September 20, 2021
Time: 2:55 p.m. ET/11:55 a.m. PT
Event: Fireside Chat

Cantor Global Healthcare Conference
Date: Wednesday, September 29, 2021
Time: 2:00 p.m. ET/11:00 a.m. PT
Event: Company Presentation

Webcasts of the H.C. Wainwright, Oppenheimer, and Cantor presentations will be available online in the investor relations section of the company’s website at https://ir.alpineimmunesciences.com/events. A replay of the presentations will be available on the company website for 90 days following the webcast.

About Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005744/en/

Investor Relations

Alex Sharif

Director, Investor Relations and Corporate Development

Alpine Immune Sciences, Inc.

206-788-4545

ir@alpineimmunesciences.com

Media Relations

Kelli Perkins

Red House

Kelli@redhousecomms.com

Source: Alpine Immune Sciences, Inc.

FAQ

What are the key conferences Alpine Immune Sciences is attending in September 2021?

Alpine Immune Sciences will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, Oppenheimer Fall Healthcare Summit on September 20, and Cantor Global Healthcare Conference on September 29.

When will the webcasts of Alpine's presentations be available?

The webcasts will be available on-demand starting from their respective presentation times and for 90 days following each event on the company's investor relations website.

What is the stock symbol for Alpine Immune Sciences?

The stock symbol for Alpine Immune Sciences is ALPN.